Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [10]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [8]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 50-0369-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD36 Monoclonal Antibody (eBioNL07 (NL07)), eFluor™ 660, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The monoclonal antibody eBioNL07 recognizes human CD36, which is a member of the class B scavenger receptor family. CD36 was originally identified as a platelet-membrane glycoprotein also called glycoprotein IV and a receptor for thrombospondin-1 (TSP-1) and extracellular matrix proteins. Binding to TSP-1 is in the CLESH (CD36 LIMP-II Emp sequence homology) domain of CD36. CD36 expression is broad and includes microvascular (but not large vessel) endothelium, adipocytes, skeletal muscle, dendritic cells, epithelia of the retina, breast, and intestine, smooth muscle cells, and hematopoietic cells, including erythroid precursors, platelets, monocytes/macrophages, DCs and megakaryocytes. Expression on platelets is absent on Nak-a negative donors. Unlike other scavenger receptor, CD36 binds LDL that has been exposed to "minimally" oxidizing conditions. CD36 is also a fatty acid translocase (FAT) necessary for the transport of long-chain fatty acids (LCFAs) and therefore may play a role in atherosclerosis.
- Antibody clone number
- eBioNL07 (NL07)
- Concentration
- 5 µL/Test
Submitted references Mitochondrial RNA modifications shape metabolic plasticity in metastasis.
Genome-Wide Transcriptional Regulation of the Long Non-coding RNA Steroid Receptor RNA Activator in Human Erythroblasts.
CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.
Spatial and Single-Cell Transcriptional Profiling Identifies Functionally Distinct Human Dermal Fibroblast Subpopulations.
IRGM1 regulates oxidized LDL uptake by macrophage via actin-dependent receptor internalization during atherosclerosis.
Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas.
Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.
Methionine 156 in the immunodominant domain of CD36 contributes to define the epitope recognized by the NL07 MoAb.
Platelet activation and inhibition of malarial cytoadherence by the anti-CD36 IgM monoclonal antibody NL07.
Analysis of the human CD36 leucocyte differentiation antigen by means of the monoclonal antibody NL07.
Delaunay S, Pascual G, Feng B, Klann K, Behm M, Hotz-Wagenblatt A, Richter K, Zaoui K, Herpel E, Münch C, Dietmann S, Hess J, Benitah SA, Frye M
Nature 2022 Jul;607(7919):593-603
Nature 2022 Jul;607(7919):593-603
Genome-Wide Transcriptional Regulation of the Long Non-coding RNA Steroid Receptor RNA Activator in Human Erythroblasts.
Sawaengdee W, Cui K, Zhao K, Hongeng S, Fucharoen S, Wongtrakoongate P
Frontiers in genetics 2020;11:850
Frontiers in genetics 2020;11:850
CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.
Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, Del Genio C, Canfield K, DiRenzo J, Wells W, Gaur A, Robey RB, Guo JY, Powles RL, Sotiriou C, Pusztai L, Febbraio M, Cheng C, Kinlaw WB, Kurokawa M
Cell reports 2019 Dec 10;29(11):3405-3420.e5
Cell reports 2019 Dec 10;29(11):3405-3420.e5
Spatial and Single-Cell Transcriptional Profiling Identifies Functionally Distinct Human Dermal Fibroblast Subpopulations.
Philippeos C, Telerman SB, Oulès B, Pisco AO, Shaw TJ, Elgueta R, Lombardi G, Driskell RR, Soldin M, Lynch MD, Watt FM
The Journal of investigative dermatology 2018 Apr;138(4):811-825
The Journal of investigative dermatology 2018 Apr;138(4):811-825
IRGM1 regulates oxidized LDL uptake by macrophage via actin-dependent receptor internalization during atherosclerosis.
Xia F, Li R, Wang C, Yang S, Tian L, Dong H, Pei C, He S, Jiang P, Cheng H, Fang S, Li H, Xu H
Scientific reports 2013;3:1867
Scientific reports 2013;3:1867
Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas.
Zhang Y, Young ED, Bill K, Belousov R, Peng T, Lazar AJ, Pollock RE, Simmons PJ, Lev D, Kolonin MG
Stem cell research 2013 Sep;11(2):772-81
Stem cell research 2013 Sep;11(2):772-81
Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.
Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I
Oncogene 2013 May 2;32(18):2249-60, 2260.e1-21
Oncogene 2013 May 2;32(18):2249-60, 2260.e1-21
Methionine 156 in the immunodominant domain of CD36 contributes to define the epitope recognized by the NL07 MoAb.
Gruarin P, Ulliers D, Thorne RF, Alessio M
Molecular and cellular biochemistry 2000 Nov;214(1-2):89-95
Molecular and cellular biochemistry 2000 Nov;214(1-2):89-95
Platelet activation and inhibition of malarial cytoadherence by the anti-CD36 IgM monoclonal antibody NL07.
Alessio M, Greco NJ, Primo L, Ghigo D, Bosia A, Tandon NN, Ockenhouse CF, Jamieson GA, Malavasi F
Blood 1993 Dec 15;82(12):3637-47
Blood 1993 Dec 15;82(12):3637-47
Analysis of the human CD36 leucocyte differentiation antigen by means of the monoclonal antibody NL07.
Alessio M, Ghigo D, Garbarino G, Geuna M, Malavasi F
Cellular immunology 1991 Oct 15;137(2):487-500
Cellular immunology 1991 Oct 15;137(2):487-500
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Mouse IgM Isotype Control eFluor® 660 (Product # 50-4752-82) (blue histogram) or Anti-Human CD36 eFluor® 660 (purple histogram). Cells in the monocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 (A-E) Comparison of sarcomas and reprogrammed-sarcomas in terms of achieving terminal differentiation as measured by acquisition of the terminal phenotype (both bone via Alizarin Red S staining for calcium deposition and fat via Oil-Red-O staining for lipid accumulation) AND cessation of proliferation via loss of Ki67. (F) MSCs differentiated as controls into bone and fat. (Oil-Red-O images are magnified 10-fold to accentuate lipid formation associated with each cell). Scale bars=10um.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 (A) Myc RT-PCR in parental and reprogrammed sarcoma cells following three weeks in either maintenance (control), adipogenic (fat) or osteogenic (bone) differentiation medium. Chromatin immunoprecipitation of the myc promoter using anti-H3K4triMe (B) or anti-HEK27triMe (C) antibodies in either maintenance (control), adipogenic (fat) or osteogenic (bone) differentiation medium. (D) DNA-promoter methylation analysis showing all statistically differentially methylated promoters (T-Test p
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 IRGM1 controls CD36 internalization by regulating actin polymerization. BMMPhi from either Irgm1 +/+ or Irgm1 -/- mice was labeled with CD36 cross-linking antibody. Then, they were either left in 37degC to cross-link CD36 or on ice. Cells were then washed by cold acid wash buffer to deplete surface CD36. Confocal microscope and flow cytometry were used to detect and quantify CD36 internalization respectively. (a and b n = 8/group, p = 0.004). F-actin polymerization was detected by phalloidin-FITC in BMMPhi from either Irgm1 +/+ or Irgm1 -/- mice with or without oxLDL. The fluorescence was measured by confocal microscope and quantified by flow cytometry (c and d, n = 3, p = 0.02). Data are represented as mean +- SEM.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4. CD36 Is Essential for Survival of Lapatinib-Resistant Cells (A and B) Transient siRNA transfections were performed with Lipofectamine RNAiMAX (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. (A) Knockdown of CD36 was confirmed by western blot 72 h after transfection. (B) Apoptosis was measured by Annexin V staining via flow cytometry 72 h after transfection (mean +- SEM from 3 experiments). (C) BT474 and rBT474 cells treated with the CD36 inhibitor sulfosuccinimidyl oleate (SSO) and lapatinib. Cell proliferation was measured by live-cell imaging using an Incucyte Zoom imager at 48 and 96 h of drug treatment. The results depict the average change in confluency from 3 replicate wells +- SD from 3 experiments. (D) Treatment scheme for xenograft experiment presented in (E). (E) BT474 and rBT474 xenografts were established in 6-week-old immunodeficient NSG mice. When tumors reached 300 mm 3 , mice were dosed with lapatinib (100 mg/kg) or vehicle twice a day by oral gavage and 10 mug JC63.1 or IgA control once every 3 days. Tumors were measured every 3 days, and mice were sacrificed after 33 days of treatment. Data are shown as average tumor volume +- SEM. The significance of the bar graphs in (B) and (C) was assessed by unpaired Student's t test, with the threshold of significance set at *p < 0.05. The significance of the growth curves in (E) was assessed using the ""statmod"" R package, with significance set at *p < 0.05 after Benjami
